论文部分内容阅读
目的观察经动脉灌注化疗栓塞治疗原发性肝癌的疗效与不良反应。方法选择210例原发性肝癌患者,经动脉灌注化疗栓塞治疗,首次治疗后每隔1个月复查CT、AFP、肝功能及一般实验室检查。观察临床疗效与不良反应。结果全组CR3例,PR122例NC45例PD30例。有效率(CR+PR)59.5%,获益率(CR+PR+NC)85.7%。术后观察5～14d,发热(体温>38℃)115例,肝区疼痛163例,恶心呕吐52例,ALT较术前明显升高21例,BIL明显升高17例,WBC<4×109/l有14例。治疗后AFP降低153例,AFP升高26例,AFP<20μg/L31例。结论经动脉灌注化疗栓塞治疗原发性肝癌临床疗效确切,不良反应少,是一种安全有效的治疗原发性肝癌的方法,值得在基层医院进一步推广。
Objective To observe the efficacy and adverse reactions of transcatheter arterial chemoembolization in the treatment of primary liver cancer. Methods 210 patients with primary liver cancer were selected and treated with arterial infusion chemotherapy and embolization. CT, AFP, liver function and general laboratory examination were reviewed every other month after the first treatment. To observe the clinical efficacy and adverse reactions. Results The whole group CR3 cases, PR122 cases NC45 cases PD30 cases. The effective rate (CR + PR) was 59.5%, and the rate of return (CR + PR + NC) was 85.7%. 115 cases of fever (body temperature> 38 ℃), 163 cases of liver pain and 52 cases of nausea and vomiting were observed 5 to 14 days after operation. ALT was significantly higher than that before operation in 21 cases, BIL was significantly increased in 17 cases, WBC <4 × 109 / l in 14 cases. AFP decreased after treatment in 153 cases, AFP increased in 26 cases, AFP <20μg / L31 cases. Conclusions Transcatheter arterial chemoembolization in the treatment of primary liver cancer has definite clinical curative effect and few adverse reactions. It is a safe and effective method to treat primary hepatocellular carcinoma and should be further popularized in the primary hospital.